IC50: 7.92 μM (OVCAR-8 cell)
Isobavachalcone (6.0-48.0 μM; 72 hours; OVCAR-8, PC3, A549, MCF-7, L-02 and HUVEC cells) treatment inhibits the proliferation of human cancer cells. Isobavachalcone inhibits PC3, A549, MCF-7, L-02 and HUVEC cells growth with IC50 values of 15.06 μM, 32.2 μM, 28.29 μM, 31.61 μM and 31.3 μM, respectively. Isobavachalcone (0-18 μM; 6 hours; OVCAR-8 and PC3 cells) treatment results in a concentration-and time-dependent down-regulation of the Ser-473 phosphorylation of Akt and GSK3b phosphorylation. Isobavachalcone (0-18 μM; 72 hours; OVCAR-8 and PC3 cells) treatment causes apoptosis via caspase- and ROS-involved mitochondrial pathway.
Cell Proliferation Assay
Western Blot Analysis
Apoptosis Analysis
Isobavachalcone (20 mg/kg; intraperitoneal injection; for 0.5-24 hours; female Kunming mice) treatment results in an increase in blood glucose levels, reaching a maximum within 1 hour and maintaining until 4 hours post-dosing.